Project Grant R43DK138712
Award Date
9/20/24
Completion Date
7/31/26
Dollars Obligated
$809K
Awardee
Progenra Inc. (Z3JKMHXHFHJ6)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Malvern, PA 19355, USA
Similar Awards
The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $349,325 Project Grant under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research to Regennova, Inc., a small disadvantaged business in Durham, North Carolina. The grant supports the development of an orally-available, effective, and well-tolerated drug to treat autosomal dominant polycystic kidney disease (ADPKD), which affects over 350,000 Americans. The project aims to create and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,712,226 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Orphagen Pharmaceuticals, Inc. The grant supports the development of a novel, first-in-class class of small molecule antagonists that inhibit the gut migration of activated T cells, which is a promising therapeutic approach for treating inflammatory bowel disease (IBD). Preliminary data...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $296,022 to the University of Florida to study changes in central carbon and lipid metabolism in the exocrine pancreas in type 1 diabetes. The research aims to quantify alterations in exocrine pancreatic central carbon metabolism and determine rates of lipid turnover, using a...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,349,491 to The Trustees of the University of Pennsylvania to conduct research on reprogramming glutamine metabolism in pancreatic beta cells. The research aims to uncover the mechanisms by which the transaminase GPT2 promotes beta cell dysfunction and death, and elucidate how GPT2...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding a $306,994 pilot clinical trial to investigate the safety, compliance, and efficacy of a novel soy-tomato dietary intervention in reducing inflammation and improving outcomes for individuals with chronic pancreatitis. The project, led by researchers at The Ohio State University, aims to...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to evaluate the therapeutic potential of a new orally active small molecule in obesity-linked diabetic models. The $418,560 award, effective September 1, 2024 through April 30, 2025, supports research to: 1) analyze the pharmacokinetic profiles of a new small molecule, 2) investigate the efficacy and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This federal Project Grant award of $444,867.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the UPR transducer XBP1 in pancreatic beta cell survival and function under metabolic stress. The research will use a novel mouse model to elucidate the pathological role of XBP1s in beta cell integrity under metabolic stress, in order to...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...